A Technique for the Generation of Influenza Virus-Like Particles via a Mammalian System
JoVE Encyclopedia of Experiments
Immunology
0 views • 3:09 min • July 8th, 2025
Loading...
Overview
This article discusses the production of virus-like particles (VLPs) as potential vaccine candidates. VLPs mimic the structure of viruses but do not contain viral genetic material, making them non-virulent and safe for use in immunization.
Key Study Components
Area of Science
- Vaccine development
- Virology
- Immunology
Background
- Virus-like particles are effective in eliciting immune responses.
- They can be produced using recombinant DNA technology.
- Influenza VLPs can be generated using specific eukaryotic expression vectors.
- Understanding the assembly and release of VLPs is crucial for vaccine efficacy.
Purpose of Study
- To outline a method for generating recombinant influenza VLPs.
- To explore the use of cationic lipid-based transfection reagents in VLP production.
- To provide a detailed protocol for transfecting mammalian cells with VLP components.
Methods Used
- Utilization of eukaryotic expression vectors containing HA, NA, and gag genes.
- Application of cationic lipid-based transfection reagents to facilitate DNA uptake.
- Incubation of transfected cells to allow for VLP assembly.
- Harvesting and filtering of VLPs from cell culture supernatants.
Main Results
- Successful transfection of mammalian cells led to VLP production.
- VLPs were harvested after 72 to 96 hours post-transfection.
- Filtration through a 0.22-micron membrane ensured removal of cellular debris.
- VLPs exhibited structural characteristics similar to native viruses.
Conclusions
- Recombinant influenza VLPs can be efficiently produced using the outlined method.
- The use of lipid-based transfection reagents is effective for VLP generation.
- This approach holds promise for developing safe and effective vaccines.
Frequently Asked Questions
What are virus-like particles?
Virus-like particles are structures that mimic the virus but do not contain any viral genetic material, making them non-infectious.
How are VLPs produced?
VLPs are produced by transfecting mammalian cells with eukaryotic expression vectors containing viral protein genes.
What is the role of cationic lipids in VLP production?
Cationic lipids facilitate the delivery of DNA into cells by forming complexes that enhance transfection efficiency.
How long does it take to harvest VLPs after transfection?
VLPs can be harvested approximately 72 to 96 hours post-transfection.
What methods are used to purify VLPs?
VLPs are purified by centrifugation and filtration to remove cellular debris.
Can VLPs be used as vaccines?
Yes, VLPs are considered promising candidates for vaccine development due to their ability to elicit immune responses without causing disease.
Executive Industry Relevance
The generation of influenza virus-like particles (VLPs) in mammalian systems enables the production of structurally authentic, non-infectious viral mimics for vaccine research and immunogenicity studies. This approach supports early-stage vaccine candidate evaluation and de-risks downstream translational efforts by providing scalable, reproducible antigen sources. The method is strategically positioned for rapid response to emerging influenza strains and portfolio diversification in vaccine R&D.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of antigenic structure and immune recognition in a controlled system.
- Supports biological de-risking by providing non-virulent, structurally relevant particles for immunogenicity assessment.
- Facilitates predictive confidence in antigen selection for vaccine development pipelines.
Screening & Assay Development
- Provides validated VLPs for use in immunoassays and neutralization screens.
- Enables assay standardization and reproducibility through consistent VLP production.
- Supports scalable preparation of antigenic material for high-throughput screening platforms.
Translational & Preclinical Research
- Aligns with disease-relevant antigen presentation for preclinical immunogenicity studies.
- Ensures continuity from discovery to preclinical validation by supplying authentic viral mimics.
- Reduces risk in translational advancement by enabling early immunological profiling.
Pipeline & Workflow Integration
This VLP generation technique integrates at the interface of antigen discovery, assay development, and preclinical immunogenicity evaluation within the vaccine R&D continuum.
- Discovery Biology: Supports hypothesis testing of antigenicity and immune response potential.
- Screening: Delivers reproducible, quantitative VLP outputs for assay readiness.
- Analytics: Enables measurement of immune recognition and comparative antigenicity across constructs.
- Translational Research: Provides a bridge to preclinical vaccine candidate assessment with structurally relevant particles.
- Enterprise Reuse: Establishes a platform for rapid adaptation to new influenza strains or other viral targets.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in antigen selection and reduces mechanistic ambiguity in immune response studies.
- Operational Value: Standardizes VLP production for reproducibility and scalability across R&D teams.
- Strategic Value: Accelerates go/no-go decisions and enhances capital efficiency in vaccine portfolio management.
- Portfolio Impact: Enables risk-adjusted prioritization of vaccine candidates and supports rapid response to emerging threats.
Implementation Considerations
- Requires expertise in mammalian cell culture and recombinant DNA transfection.
- Demands access to cell culture infrastructure and analytical tools for VLP characterization.
- Necessitates cross-team standardization of transfection and harvest protocols for reproducibility.
- May require adaptation for different viral targets or host cell systems.
- Dependent on optimization of DNA ratios and transfection conditions for maximal VLP yield.
Biopharma FAQs
Why is null hypothesis testing important for VLP antigen validation?
Null hypothesis testing enables teams to rigorously assess whether observed immune responses to VLPs are statistically significant, supporting confident target validation and reducing false positives in antigen selection.
How does independent variable isolation in transfection improve discovery workflows?
Isolating variables such as DNA ratios and transfection conditions allows for systematic optimization of VLP yield and quality, streamlining early discovery and ensuring reproducible outputs for downstream assays.
What do quantitative VLP yield measurements enable in R&D?
Quantitative measurement of VLP yield provides objective criteria for comparing production conditions, informing process optimization and supporting data-driven advancement decisions in vaccine development pipelines.
Why are replication requirements critical for cross-functional VLP studies?
Replication ensures that VLP production and immunogenicity results are consistent across experiments and teams, facilitating reliable data sharing and collaborative decision-making in multi-site R&D environments.
What statistical analysis capabilities are needed before VLP implementation?
Robust statistical analysis is required to evaluate VLP yield, purity, and immunogenicity data, enabling teams to set acceptance thresholds and validate reproducibility prior to broader implementation in vaccine workflows.
08:52
Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
Related Videos
0 Views
08:10
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
Related Videos
0 Views
05:15
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay
Related Videos
0 Views
11:31
Generation of Recombinant Influenza Virus from Plasmid DNA
Related Videos
0 Views
10:05
High-throughput Detection Method for Influenza Virus
Related Videos
0 Views
03:05
Generation of Chikungunya Virus-Like Particles Using Baculovirus Expression System in Insect Cells
Related Videos
0 Views
02:58
Generating Recombinant Live-Attenuated Influenza Viruses for Vaccines
Related Videos
0 Views
12:18
Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System
Related Videos
0 Views
06:56
Influenza Virus Propagation in Embryonated Chicken Eggs
Related Videos
0 Views
10:39
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Related Videos
0 Views
Last updated: 15 August 2026